Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,676 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type II Clear all
Recruiting Early Phase 1 Interventional

SGLT2i, Hepatic Glucose Production, and SNS

NCT07053293
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

NCT01724814
View directory record Official record
Conditions
Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
HM12460A, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

NCT02330549
View directory record Official record
Conditions
Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Cenicriviroc 150 mg, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Not applicable Interventional Results available

Closed Loop Glucose Control in Patients With Type 2 Diabetes

NCT05386849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
FUSION closed loop glucose control system
Device
Lead sponsor
Ideal Medical Technologies
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Providing Genetic Risk Information on Lifestyle Behaviors in African Americans

NCT07833384
View directory record Official record
Conditions
Diabetes, Hypercholesterolaemia, Hypertension, Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Heart Failure, CAD - Coronary Artery Disease, Stroke Risk, Cardiac Arrythmias, Genetics Hypertension, Genetics, Pharmacogenomics, Pharmacogenomic Testing for Medication Management, Cancer Genetics
Interventions
Color Genomics Genetic Testing Panels
Genetic
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00611884
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin glargine, insulin degludec, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Inglewood, California • Los Angeles, California • Redlands, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Not applicable Interventional

Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM)

NCT04269655
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cloud-Based Continuous Glucose Monitoring
Device
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

NCT05514535
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
145
States / cities
Sheffield, Alabama • Glendale, Arizona • Mesa, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

NCT03324776
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Model Clinical Research LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Not applicable Interventional

Improving Diabetes Outcomes Through Lifestyle Change (IDOLc)Study

NCT01665989
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Group Lifestyle Program, Usual Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

NCT01774968
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Regular U-500 Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pistachios Blood Sugar Control, Heart and Gut Health

NCT04056208
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Diseases
Interventions
Pistachio, Usual care
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 1 Interventional Results available

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

NCT02588950
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
U-500R
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 16, 2026, 10:40 AM EDT
Enrolling by invitation Not applicable Interventional

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

NCT07605390
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Epic-Based Clinician Notification, Usual Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Not applicable Interventional

Pilot Study to Assess Pre-packaged, Portion-controlled Meal Plan on Weight Loss

NCT00593476
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
PCD, DSE
Other
Lead sponsor
Temple University
Other
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4

NCT00574340
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hypoglycemic Clamp
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors

NCT07421518
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
SGLT-2 inhibitor (Sotagliflozin), Insulin withdrawal test (IWT)
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

NCT03015519
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Morehead City, North Carolina • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes

NCT00753181
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Nutritional Formula, Usual diet, Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Bloomington, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Not applicable Interventional Results available

Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being

NCT02723019
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiometabolic Conditions, Behavioral Health Concerns
Interventions
Volunteer Peer Mentor+Behavioral Health Nurse
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

NCT02682901
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
Cycloset, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Not applicable Interventional

The Effect of Exercise Training Intensity in Patients With Type 2 Diabetes

NCT01417845
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
High Intensity Exercise Training, Moderate Intensity Exercise Training
Behavioral
Lead sponsor
University of Central Arkansas
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Conway, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 16, 2026, 10:40 AM EDT